Clinical Trial Update: MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating MIT-001 to prevent oral mucositis caused by concurrent chemoradiation in patients with head and neck squamous cell carcinoma; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Oral Mucositis

Drugs mentioned

• MIT-001 (MIT-001)

Snippet

Sponsor: MitoImmune Therapeutics | Conditions: Head and Neck Squamous Cell Carcinoma, Oral Mucositis | Phase 2 | Status: ACTIVE_NOT_RECRUITING